Product Description
Vascular endothelial growth factor receptor 1 (VEGFR1) also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.
Biovision | 7237 | Human CellExp VEGF R1 /Flt-1 human recombinant DataSheet
Biomolecule/Target: VEGFR1
Synonyms: FLT, VEGFR1, FLT1
Alternates names: FLT, VEGFR1, FLT1
Taglines: Plays an essential role in the development of embryonic vasculature
NCBI Gene ID #: NM_013110
NCBI Gene Symbol: IL7
Gene Source: Human
Accession #: P56478
Recombinant: Yes
Source: HEK 293 cells
Purity by SDS-PAGEs: 98%
Assay: SDS-PAGE
Purity: N/A
Assay #2: HPLC
Endotoxin Level: < 0.1 ng/g of protein (<1EU/g).
Activity (Specifications/test method): Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 2-25 ng/ml.
Biological activity: Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 2-25 ng/ml.
Results: N/A
Binding Capacity: N/A
Unit Definition: N/A
Molecular Weight: The protein is fused with 6×His tag at the N-terminus, has a calculated MW of 50.6 kDa. The predicted N-terminus is Asp 34. DTT-reduced Protein migrates as 55-60 kDa due to glycosylation.
Concentration: N/A
Appearance: Lyophilized powder
Physical form description: Lyophilized from 0.22 m filtered solution in PBS. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.
Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
Amino acid sequence: N/A